Durable Responses Move Kite Toward Pivotal Trial For CAR T-Cell Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Kite hopes to begin a registrational trial for KTE-C19 in diffuse large B-cell lymphoma by 2015, file a BLA in 2016 and launch the first chimeric antigen receptor T-cell therapy for cancer by 2017. Results from a Phase I/II trial being conducted by the National Cancer Institute show ongoing remissions up to 22 months in patients with very short life expectancies.
You may also be interested in...
Acute Lymphoblastic Leukemia Poised To Be First, Fast Driver Of CAR Immunotherapy
Given high complete response rates in early studies showcased at the American Society of Hematology’s recent annual meeting, acute lymphoblastic leukemia is a likely launch indication for chimeric antigen receptor immunotherapy. But while the results in B-cell malignancies are very promising so far, autologous CAR therapies are complex, and toxicities need to be carefully managed.
Medtronic Creates Chief Technology And Innovation Officer Role
Ken Washington, the former general manager of consumer robotics, will help the company “accelerate innovation-driven growth.”
Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.